ADMA Biologics Inc (ADMA) News
Filter ADMA News Items
ADMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADMA News Highlights
- ADMA's 30 day story count now stands at 17.
- Over the past 22 days, the trend for ADMA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ADMA are ABR, DEC and LUNG.
Latest ADMA News From Around the Web
Below are the latest news stories about ADMA BIOLOGICS INC that investors may wish to consider to help them evaluate ADMA as an investment opportunity.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets GoalsCytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response. |
Milestone Pharma (MIST) Down on Regulatory Update for EtripamilMilestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT. |
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority TagMerck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024. |
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? |
Should You Buy Adma Biologics (ADMA) After Golden Cross?Is it a good or bad thing when a stock experiences a golden cross technical event? |
Are Medical Stocks Lagging Brainsway (BWAY) This Year?Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Adma Biologics (ADMA) have performed compared to their sector so far this year. |
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC CandidateGSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093. |
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%. |
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares ManagementNew $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced the Company has executed a definitive credi |
Acadia (ACAD) Rises 35% on Positive Patent Ruling for NuplazidAcadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response. |